Often autoimmune conditions involve vague and overlapping symptoms, making them difficult to identify. Currently, many patients with autoimmune disease experience delayed referral, diagnosis, and treatment. This can result in permanent joint damage and an even smaller chance of remission
Disease-specific autoimmune screening in primary care can help patients get the care they need sooner by mitigating the impact of rheumatologist shortages and changing population trends. Antinuclear antibody (ANA) testing alone is not enough to definitively diagnose an autoimmune disease, because symptoms across disorders can be vague, vary from patient to patient, and overlap. Expedite autoimmune diagnosis and improve outcomes with comprehensive autoimmune testing that is more specific than ANA alone.
Antinuclear antibody (ANA) screening alone cannot diagnose the specific autoimmune condition. In fact, positive ANA results do not definitively rule out healthy patients either, so referrals based only on ANA results can lead to unnecessary rheumatologist visits. Comprehensive autoimmune screening delivers more answers with a single test code, so PCPs can make the right referral the first time—and help limit disease progression. Quest’s autoimmune screening panels test for ANA plus the most informative disease-specific markers, so you can help narrow down the diagnosis earlier.
Consult with one of the most experienced clinical diagnostics teams in the industry. Get the clinical decision support your organization needs. Our staff of medical and scientific experts are ready to provide support and share key information to help keep you up-to-date, and quickly connect you to the resources you need—including 600+ MDs and PhDs, and 40+ Genetic Counselors.
